Bio Green Med Solution, Inc. (BGMS): Entry into a Material Definitive Agreement
Bio Green Med Solution, Inc. (BGMS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 10, 2026 (the “Effective Date”), between Bio Green Med Solution, Inc., a Delaware corporation (the “ Company ”), and _______, an ind
- Instrument
- Common Stock
- Shares
- 1,103,338 shares
- Price per share
- $0.72 per share
- Gross proceeds
- $794,403
- Use of proceeds
- general corporate and operating purposes
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
A new securities purchase agreement typically precedes closing of a financing; until the full exhibit is reviewed for share/warrant mechanics, the market may price in dilution risk and uncertainty around capital needs.
Market read
This is a primary-source financing disclosure for BGMS, relevant for traders focused on dilution/financing overhang and near-term liquidity/float changes.
What to watch
Traders should verify the missing deal economics (purchase price, number of shares, any warrants/discounts, registration rights, and closing conditions) because those determine dilution and immediate float impact.
Background
The SEC 8-K reports BGMS’s entry into a material definitive agreement and an unregistered equity securities issuance under Securities Act rules (Regulation S referenced).
Ticker impact
BGMS filed an 8-K disclosing entry into a securities purchase agreement for an unregistered equity issuance (Item 1.01/3.02).
Near-term downside risk from dilution/financing overhang; magnitude depends on deal size and terms (not provided in the excerpt).
The article is a primary SEC 8-K for a definitive agreement tied to unregistered sales; however, the excerpt omits key economic terms (purchase price, share count, conversion/discount mechanics), limiting precision on impact size.
Market effects
Microcap biotech/healthcare issuers often face higher dilution risk when using unregistered Reg S-style placements; could modestly affect peer sentiment if similar financing structures are common.
Primarily US-listed microcap sentiment; limited broader regional spillover.
Low—deal appears company-specific with no cross-border operational catalyst described.
Counterpoint
If the placement is small or structured with limited dilution (e.g., fixed-price common issuance without conversion features), the overhang may be limited and the stock could stabilize after terms are digested.
Key entities
- issuerBio Green Med Solution, Inc.
Company filing the 8-K and entering the securities purchase agreement.
- counterpartyPurchaser
Unnamed individual in the excerpt; the agreement contemplates an offshore transaction under Regulation S.
- agreementSecurities Purchase Agreement (Ex-10.1)
Defines the terms for the company to issue and sell securities to the purchaser; key economic terms are redacted in the excerpt.
